publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
rvsvdgzebovgp
also
design
recombin
vesicular
stomat
viru
pseudotyp
ebola
zair
glycoprotein
standard
templat
key
consider
riskbenefit
assess
b
r
c
brighton
collabor
viral
vector
vaccin
safeti
work
group
form
evalu
safeti
characterist
live
recombin
viral
vector
vaccin
recent
public
describ
live
attenu
recombin
vesicular
stomat
viru
rvsv
chimer
viru
vaccin
clark
et
al
rvsv
vector
system
explor
platform
develop
multipl
vaccin
paper
review
molecular
biolog
featur
rvsv
vector
system
follow
templat
detail
safeti
characterist
rvsv
vaccin
zair
ebolaviru
zebov
rvsvzebov
vaccin
live
replic
compet
vector
vsv
glycoprotein
g
gene
replac
glycoprotein
gp
gene
zebov
multipl
copi
gp
express
assembl
viral
envelop
respons
induc
protect
immun
vaccin
design
origin
construct
nation
microbiolog
laboratori
public
health
agenc
canada
develop
newlink
genet
corp
merck
co
final
stage
registr
merck
vaccin
attenu
delet
princip
virul
factor
vsv
g
protein
also
remov
primari
target
antivector
immun
vaccin
caus
toxic
intramuscular
im
intracrani
inject
nonhuman
primat
reproduct
development
toxic
rat
model
multipl
studi
cynomolgu
macaqu
immun
im
wide
rang
viru
dose
rapidli
develop
zebovspecif
antibodi
measur
igg
elisa
neutral
assay
fulli
protect
lethal
challeng
zebov
viru
peopl
receiv
vaccin
clinic
trial
vaccin
proven
safe
well
toler
first
day
vaccin
mani
vaccine
experi
mild
acutephas
reaction
fever
headach
myalgia
arthralgia
short
durat
period
associ
lowlevel
viremia
activ
antivir
gene
increas
level
chemokin
cytokin
oligoarthr
rash
appear
second
week
occur
low
incid
typic
mildmoder
sever
selflimit
vaccin
use
phase
iii
efficaci
trial
west
african
ebola
epidem
show
protect
ebola
viru
diseas
subsequ
deploy
emerg
control
ebola
outbreak
central
africa
templat
recombin
viral
vector
express
heterolog
antigen
antibodi
repres
promis
platform
develop
novel
vaccin
therapi
human
anim
infecti
diseas
cancer
develop
new
viral
vector
remodel
vector
backbon
improv
biolog
activ
incorpor
new
foreign
protein
exist
vector
platform
result
uniqu
viral
product
requir
assess
safeti
innat
adapt
immun
respons
manufactur
regulatori
pathway
import
understand
chimer
viral
vector
differ
wildtyp
progenitor
base
modif
within
vector
backbon
effect
ad
heterolog
gene
may
influenc
pathogenesi
particularli
true
replic
attenu
vaccin
distinguish
replic
defect
vector
eg
adenovirus
alphaviru
replicon
herp
simplex
virus
live
vector
attenu
due
host
rang
restrict
eg
modifi
vaccinia
ankara
sendai
newcastl
diseas
virus
gener
replic
vaccin
proven
effect
gener
rapid
durabl
protect
viral
infect
number
ration
develop
recombin
replic
attenu
viral
vector
vaccin
clinic
develop
near
licensur
reach
commerci
among
promin
platform
construct
vaccin
vaccinia
viru
veterinari
applic
measl
viru
adenoviru
type
alphavirus
sindbi
venezuelan
equin
enceph
viru
flavivirus
includ
dengu
viru
yellow
fever
viru
cytomegaloviru
vesicular
stomat
viru
subject
paper
brighton
collabor
wwwbrightoncollaborationorg
form
intern
voluntari
collabor
enhanc
scienc
vaccin
safeti
research
recognit
need
domain
brighton
collabor
creat
viral
vector
vaccin
safeti
work
group
octob
analog
valu
embodi
standard
case
definit
advers
event
follow
immun
aefi
believ
standard
templat
describ
key
characterist
novel
vaccin
vector
complet
maintain
latest
research
facilit
scientif
discours
among
key
stakehold
increas
transpar
compar
inform
intern
aid
vaccin
initi
iavi
alreadi
develop
intern
tool
assess
riskbenefit
differ
viral
vector
sponsorship
iavi
gracious
share
tool
adapt
broader
use
standard
templat
collect
key
inform
riskbenefit
assess
viral
vector
vaccin
tool
aim
identifi
potenti
major
hurdl
gap
would
need
address
develop
vector
vaccin
templat
collect
inform
characterist
wild
type
viru
vector
deriv
well
known
effect
propos
vaccin
vector
anim
human
manufactur
featur
toxicolog
potenc
nonclin
studi
human
use
overal
advers
effect
risk
assess
follow
process
describ
brighton
collabor
websit
http
cmsbrightoncollaborationorg
html
brighton
collabor
form
octob
includ
member
clinic
academ
public
health
regulatori
industri
background
appropri
expertis
interest
composit
work
refer
group
well
result
webbas
survey
complet
refer
group
subsequ
discuss
work
group
view
http
wwwbrightoncollaborationorginternetenindexworkinggroupshtml
workgroup
meet
via
email
monthli
confer
call
coordin
secretariat
anticip
eventu
developersresearch
viral
vector
vaccin
especi
clinic
develop
complet
templat
submit
brighton
collabor
peer
review
eventu
public
vaccin
follow
promot
transpar
templat
post
maintain
brighton
collabor
websit
userefer
variou
stakehold
furthermor
recogn
rapid
pace
new
scientif
develop
domain
rel
aefi
case
definit
hope
maintain
complet
templat
wiki
style
help
brighton
collabor
vector
vaccin
commun
expert
paper
preced
recent
brighton
collabor
public
clark
et
al
describ
histori
rational
develop
vsv
replic
vector
platform
natur
histori
parent
vsv
virus
construct
recombin
vaccin
pseudotyp
heterolog
protein
stimul
humor
cellular
immun
attenu
strategi
applic
anim
model
test
safeti
efficaci
manufactur
statu
clinic
develop
underli
principl
explain
clark
et
al
critic
background
present
paper
number
gener
point
reemphas
addit
background
provid
facilit
understand
recombin
rvsv
platform
appli
develop
vaccin
viral
hemorrhag
fever
comment
follow
templat
provid
specif
featur
advanc
rvsv
vector
develop
vaccin
ebola
viru
diseas
vsv
glycoprotein
g
entir
delet
replac
correspond
glycoprotein
gp
zair
ebolaviru
rvsvdgzebovgp
vaccin
current
design
develop
merck
co
kenilworth
nj
usa
registr
process
aspect
rvsv
technolog
special
interest
vaccin
develop
vsv
neg
sens
singlestrand
rna
viru
belong
famili
rhabdovirida
genu
vesiculoviru
wide
explor
vaccin
develop
infecti
diseas
cancer
oncolyt
viru
b
vsv
caus
selflimit
diseas
hors
pig
cattl
may
either
asymptomat
caus
mild
flulik
syndrom
human
thu
natur
attenu
vector
backbon
develop
human
vaccin
therapi
c
advantag
vsv
vector
includ
low
preval
immun
vector
popul
target
immun
ii
viral
rna
integr
host
pose
littl
risk
oncogenesi
mutagenesi
iii
larg
foreign
transgen
packag
express
iv
viru
may
pseudotyp
heterolog
viral
glycoprotein
present
envelop
natur
conform
two
major
vsv
serotyp
vsvindiana
vsvnew
jersey
vsvindiana
vsvi
basi
current
vaccin
candid
relat
vesiculovirus
isfahan
viru
maraba
viru
distantli
relat
rhabdovirus
rabi
viru
also
explor
viral
vector
e
vsv
genom
consist
nucleotid
encod
five
major
protein
vsv
glycoprotein
g
locat
viral
envelop
respons
attach
cell
fusion
endosom
membran
low
ph
releas
viral
genom
rna
cytoplasm
g
protein
also
elicit
protect
immun
vsv
f
use
revers
genet
system
vsv
vector
construct
express
gene
diverg
speci
includ
mani
virus
eg
ebola
viru
marburg
viru
lassa
fever
viru
hiv
influenza
viru
hpv
other
see
templat
bacteria
tumor
antigen
construct
portion
vsv
g
protein
retain
facilit
express
enabl
fusion
intern
recombin
viru
vsv
vector
complet
lack
vsv
g
gene
vsvdg
must
reconstitut
attach
fusion
bud
releas
function
one
protein
encod
heterolog
envelop
gene
case
rvsvdginfluenza
exampl
vsv
g
replac
influenza
hemagglutinin
ha
neuraminidas
na
viru
express
ha
na
vector
produc
replicationcompet
pseudotyp
viru
sinc
protein
play
role
attach
na
need
viru
releas
host
cell
similarli
case
henipaviru
nipah
pseudotyp
express
nipah
glycoprotein
g
respons
cell
attach
produc
replic
viru
unless
fusion
protein
f
protein
nipah
glycoprotein
gp
ebola
zair
coexpress
g
replic
rvsvdg
pseudotyp
glycoprotein
gp
deriv
mani
differ
filovirus
ebola
zair
ebola
sudan
ebola
reston
marburg
bundibugyo
tai
forest
lloviu
construct
gp
provid
viru
attach
class
fusion
function
advanc
vaccin
candid
describ
templat
rvsvdgzebovgp
express
zair
ebola
viru
zebov
gp
place
vsvi
g
protein
h
revers
genet
system
produc
rvsvdgzebovgp
involv
cotransfect
cell
plasmid
contain
entir
vsv
genom
g
delet
replac
zebov
gp
togeth
helper
plasmid
express
vsv
n
p
l
gene
transcript
plasmid
control
bacteriophag
polymeras
suppli
babi
hamster
kidney
cell
express
done
rvsvdgzebovgp
exogen
recombin
vaccinia
express
polymeras
rvsvdgzebovgp
construct
fulllength
gp
anchor
viral
envelop
wherea
nativ
zebov
express
abund
solubl
form
gp
without
transmembran
domain
solubl
gp
sgp
may
act
decoy
antibodi
contribut
evas
neutral
antibodi
filoviru
infect
rvsvdgzebovgp
gener
sgp
effici
neutral
antibodi
wildtyp
zebov
j
full
length
heterolog
gp
incorpor
rvsv
particl
retain
typic
bullet
shape
morpholog
viral
envelop
decor
zebov
gp
spike
instead
vsv
g
protein
spike
gp
spike
compos
disulfid
link
subunit
three
subunit
form
propellerlik
trimer
consist
receptor
bind
domain
glycosyl
mucinlik
domain
glycan
cap
glycan
hypothes
shield
epitop
neutral
antibodi
howev
uncertain
sinc
neutral
occur
prior
cleavag
mucinlik
domain
endosom
moreov
mutat
rvsvdgzebovgp
lack
glycan
effici
elicit
neutral
antibodi
mice
k
standard
em
studi
insert
ebola
gp
rvsv
particl
alter
typic
bulletshap
vesiculoviru
morpholog
howev
structur
zebov
gp
partial
resolv
cryoem
high
resolut
gp
pseudotyp
vsv
elucid
l
cell
target
infect
determin
viru
ligandcel
receptor
interact
may
differ
viru
pseudotyp
zebov
gp
compar
natur
vsv
although
may
overlap
tropism
certain
cell
line
suscept
vsv
zebov
jurkat
cell
insect
cell
permit
rvsvdgzebovgp
replic
primari
vivo
zebov
target
cell
thought
endotheli
cell
monocyt
macrophag
myeloid
dendrit
cell
although
also
presum
hold
true
pseudotyp
rvsv
systemat
studi
cell
type
product
infect
rvsvdgzebovgp
vivo
consist
zebov
gpspecif
tropism
limit
number
observ
suggest
endotheli
cell
target
rvsvdgzebovgp
biodistribut
studi
macaqu
show
vaccin
viru
target
lymphoreticular
tissu
merck
co
inc
kenilworth
nj
usa
newlink
genet
corp
unpublish
data
interestingli
studi
swine
unpublish
describ
templat
show
rvsvdgzebovgp
induc
selflimit
clinic
diseas
histopatholog
cell
tropism
similar
induc
wildtyp
vsv
although
pig
also
suscept
zebov
respiratori
rout
pathogenesi
distinct
caus
vsv
thu
swine
pathogenesi
hostviru
pair
appear
match
vector
backbon
rather
donor
heterolog
envelop
possibl
retent
intact
vsv
gene
virul
factor
vsv
recombin
rvsvdgzebovgp
vector
play
role
pathogenesi
swine
observ
provid
fertil
ground
futur
research
mechan
viral
pathogenesi
wild
type
zebov
rvsv
pseudotyp
zebov
gp
appear
enter
cell
macropinocytosi
gp
proteindepend
manner
cell
receptor
initi
process
remain
poorli
defin
entri
appear
involv
clathrin
contrast
vsv
g
protein
bind
lowdens
lipoprotein
receptor
enter
via
receptormedi
endocytosi
clathrindepend
pathway
ctype
lectin
eg
dcsign
put
cell
surfac
receptor
zebov
gp
howev
critic
viruscel
receptor
interact
intracellular
import
consider
immun
recognit
endosom
proteolyt
process
initi
cathepsin
proteas
bind
receptor
endosom
membran
predominantli
niemannpick
protein
cleavag
mucinlik
domain
glycan
cap
requir
receptor
bind
occur
low
ph
conform
rearrang
expos
hydrophob
fusion
loop
insert
endosom
membran
follow
intern
viral
rna
neutral
ebola
viru
antibodi
involv
multipl
differ
mechan
includ
block
cathepsinmedi
proteolyt
cleavag
block
bind
niemann
pick
receptor
inhibit
mediat
fusion
n
sinc
vsv
g
gene
delet
rvsvdgzebovgp
antivector
immun
minim
factor
primari
immun
sequenti
use
vector
express
differ
heterolog
gene
complet
delet
vsv
g
protein
replac
heterolog
transgen
rvsvdgzebovgp
result
highli
attenu
phenotyp
remov
vsv
g
princip
virul
factor
critic
attenu
sinc
construct
retain
g
portion
thereof
show
vari
degre
residu
neurovirul
inject
directli
brain
young
mice
p
attenu
rvsvdgzebovgp
vaccin
candid
extens
studi
neurovirul
featur
parent
vsv
infect
follow
intracrani
inject
anim
speci
see
templat
tabl
wherea
rvsvdgzebovgp
viru
pathogen
infant
adult
mice
caus
minim
histopatholog
without
clinic
sign
intracrani
inocul
nonhuman
primat
clinic
biochem
pathoanatom
effect
observ
mice
rat
nonhuman
primat
formal
toxicolog
studi
vaccin
administ
im
full
human
dose
see
templat
rvsvdgzebovgp
vaccin
administ
person
phase
expand
access
clinic
trial
shown
favor
safeti
profil
gener
well
toler
q
vsv
pseudotyp
propag
high
titer
mammalian
cell
although
degre
attenu
observ
compar
wildtyp
vsv
vsv
interferonsensit
viru
interferon
defici
cell
vero
cell
particularli
product
vero
cell
wide
use
manufactur
vaccin
includ
multipl
licens
live
attenu
vaccin
eg
polioviru
smallpox
viru
rotaviru
dengu
viru
rvsvdgzebovgp
viru
grow
log
plaqueform
unitsml
pfuml
vero
cell
without
serum
anim
deriv
compon
viru
clarifi
filtrat
purifi
concentr
straightforward
process
involv
enzym
digest
ultrafiltrationdiafiltr
without
chromatographi
minim
product
loss
manufactur
process
upscal
produc
larg
quantiti
vaccin
undergo
valid
dedic
facil
r
mani
live
replic
vaccin
suscept
thermal
instabl
requir
lyophil
long
term
storag
short
develop
time
rvsvdgzebovgp
west
african
ebola
emerg
vaccin
produc
store
unit
dose
contain
frozen
liquid
formul
store
interestingli
vaccin
found
stabl
thaw
held
least
week
featur
facilit
distribut
use
control
outbreak
rvsvdgzebovgp
vaccin
extens
test
nonhuman
primat
respect
immunogen
protect
efficaci
see
templat
tabl
publish
literatur
supplement
multipl
addit
studi
larg
aim
determin
immun
correl
protect
may
bridg
human
immun
respons
elicit
rvsvdgzebovgp
vaccin
effort
ongo
one
studi
igm
subclass
antibodi
suggest
play
domin
role
rvsvdgzebov
immun
compar
igg
observ
investig
inocul
rvsvdgzebovgp
follow
rapid
appear
viremia
activ
innat
immun
respons
includ
nk
cell
believ
least
partial
respons
protect
challeng
given
day
vaccin
shortli
vaccin
ie
post
exposur
vaccin
gpspecif
igg
antibodi
appear
day
vaccin
tend
peak
day
signatur
innat
immun
marker
appear
first
day
vaccin
found
correl
antibodi
level
appear
later
predomin
among
independ
marker
express
nk
cell
day
independ
correl
observ
consist
live
viral
vaccin
yellow
fever
vaccin
show
predict
innat
signatur
shape
adapt
respons
u
role
neutral
antibodi
protect
elicit
rvsvdgzebovgp
vaccin
remain
uncertain
vaccin
elicit
robust
neutral
antibodi
respons
follow
vaccin
measur
plaqu
reduct
homolog
vaccin
viru
zebov
pseudovirion
assay
neutral
titer
wildtyp
viru
appear
low
repertoir
antibodi
elicit
vaccin
yet
known
clear
neutral
monoclon
antibodi
highli
protect
passiv
immun
certain
monoclon
antibodi
abrog
infect
prevent
illnessdeath
nhp
model
even
given
day
challeng
addit
neutral
nonneutr
antibodi
function
activ
includ
adcc
phagocytosi
probabl
secondari
mediat
moreov
cooper
effect
nonneutr
antibodi
may
enhanc
potenc
neutral
antibodi
v
studi
cell
respons
nhp
human
vaccin
rvsvdgzebovgp
howev
vaccin
appear
elicit
robust
cell
respons
nhp
moreov
cell
deplet
studi
vaccin
nhp
indic
cell
play
role
protect
human
broad
cell
activ
observ
day
vaccin
zebov
specif
cytotox
cell
respons
seen
higher
vaccin
dose
pfu
consist
antibodi
predomin
mediat
protect
w
substanti
experi
accumul
safeti
immunogen
protect
efficaci
rvsvdgzebovgp
human
tabl
remark
effort
carri
coalit
multipl
intern
partner
short
period
time
intern
public
health
emerg
west
africa
pfuml
n
pfu
ml
n
pfuml
n
placebo
n
day
elig
frontlin
worker
complet
note
placehold
potenti
pediatr
clinic
trial
indefinit
hold
expand
access
trial
use
addit
ebola
outbreak
africa
studi
administ
singl
dose
except
trial
dose
administ
dose
level
nomin
statu
trial
subject
exposur
current
longterm
followup
continu
subset
studi
particip
immunocompromis
known
human
immunosuppress
steroid
potenti
wtvsv
diseas
experiment
infect
swine
defect
innat
immun
may
underli
diseas
express
vsv
exquisit
sensit
ifnab
studi
mice
lack
ifn
receptor
indic
ifn
respons
control
wtvsv
intact
innat
immun
respons
like
control
vsv
replic
neonat
infant
children
diseas
potenti
children
seem
adult
children
year
age
report
seroposit
area
survey
south
central
america
pregnanc
unborn
evid
wtvsv
caus
abort
livestock
follow
natur
infect
addit
fomit
import
mode
spread
appear
mechan
transmiss
hors
deer
fli
muscoid
fli
gnat
feed
secret
infect
livestock
reservoir
vsv
natur
bite
insect
viru
pass
vertic
adult
progeni
fli
egg
amplif
transmiss
sandfli
virem
rodent
host
known
mechan
immun
wild
type
agent
immun
acquir
neutral
antibodi
respons
viru
g
protein
locat
viral
envelop
tcell
respons
may
also
contribut
vsv
immun
map
viru
n
protein
balbc
mice
cell
epitop
presum
present
remain
major
viru
protein
nonneutr
antibodi
may
play
role
clearanc
infect
cell
viru
kill
varieti
fcmediat
phagocyt
cytotox
mechan
treatment
requir
readili
avail
diseas
caus
wild
type
agent
livestock
typic
treat
therapeut
agent
diseas
selflimit
usual
requir
treatment
secondari
bacteri
infect
delay
heal
lesion
treat
antibiot
diseas
human
usual
sever
enough
warrant
special
treatment
alpha
beta
interferon
potent
antivir
activ
cell
cultur
demonstr
antivir
activ
vivo
ribavirin
wide
use
therapeut
activ
vsv
vitro
mous
model
clinic
experi
indic
characterist
propos
vaccin
vector
inform
commentsconcern
refer
basi
attenuationinactiv
attenu
base
princip
reduct
viral
replic
virul
due
delet
vsv
g
gene
replac
ebolaviru
gp
gene
switch
envelop
glycoprotein
vsv
g
protein
zebov
gp
may
also
result
chang
cell
tropism
rvsvdgzebovgp
recombin
vsv
vector
pseudotyp
filoviru
gp
virus
fail
replic
jurkat
cell
suscept
wtvsv
ebolaviru
interestingli
howev
rvsvdgzebovgp
viru
found
infect
keratinocyt
human
featur
wtvsv
indic
even
foreign
envelop
protein
rvsvdgzebovgp
viru
share
tropism
wtvsv
viru
rvsvdgzebovgp
vaccin
viru
pathogen
peripher
rout
inocul
mice
hamster
guinea
pig
nonobes
diabeticsever
combin
immunodefici
nodscid
mice
normal
immunocompromis
shiv
infect
nonhuman
primat
neurovirul
vaccin
markedli
attenu
wherea
wtvsv
highli
neurovirul
anim
inocul
intracerebr
rout
rvsvdgzebovgp
vaccin
virul
newborn
mice
clinic
sign
signific
histopatholog
lesion
observ
nonhuman
primat
inocul
intrathalam
rout
wherea
wtvsv
highli
neurovirul
vsv
backbon
vaccin
chimera
two
vsvi
strain
like
contribut
attenu
virus
deriv
infecti
clone
hybrid
two
vsvi
subtyp
viru
grow
high
titer
cell
cultur
use
product
vero
cell
cell
line
propag
attenu
rvsvdgzebovgp
follow
im
inocul
restrict
vivo
caus
transient
lowlevel
vaccin
viremia
nonhuman
primat
human
see
section
viremia
record
adult
subject
clinic
trial
rare
exceed
copiesml
approxim
plaqueform
unitsml
viru
viral
rna
associ
vesicular
lesion
skin
arthriti
advers
event
low
frequenc
vaccin
subject
discuss
section
studi
biodistribut
persist
nonhuman
primat
describ
section
potenti
shed
transmiss
minim
shed
risk
transmiss
rvsvdgzebovgp
vaccin
infectiousimmunogen
oral
rout
nonhuman
primat
given
high
dose
contact
transmiss
includ
via
blood
fomit
mucos
rout
vaccin
viru
like
requir
high
concentr
viru
blood
shed
saliva
urin
observ
human
im
inocul
attenu
vaccin
unpublish
studi
pig
anim
inocul
vaccin
skin
snout
oronas
rout
develop
mild
vsvlike
diseas
vesicular
lesion
transmit
viru
contact
control
repeat
dose
toxicolog
studi
cynomolgu
macaqu
small
subset
monkey
show
transient
shed
viral
rna
urin
within
approxim
week
follow
im
inocul
rvsvdgzebovgp
human
inocul
im
rvsvdgzebovgp
detect
rna
saliva
urin
detect
adult
subject
saliva
adolesc
first
week
postvaccin
level
vaccin
viru
excretionssecret
appear
low
copiesml
correspond
plaqu
form
unitsml
transient
vesicular
painless
purpur
skin
lesion
note
small
number
vaccin
individu
vaccin
viru
identifi
synovi
fluid
skin
small
number
subject
qrtpcr
infecti
viru
rare
recov
one
instanc
viru
recov
vesicular
fluid
sequenc
show
mutat
origin
vaccin
siegrist
c
unpublish
known
like
reservoir
rvsvdgzebovgp
vaccin
viru
nonhuman
primat
replic
rvsvdgzebovgp
viru
clear
blood
tissu
within
first
week
inocul
immun
respons
although
rna
persist
longer
day
evid
infecti
viru
similarli
rna
recombin
vsv
express
ovalbumin
persist
lymphat
tissu
month
evid
persist
replic
viru
human
viremia
shed
larg
restrict
first
day
inocul
rare
found
day
report
beyond
point
date
mice
inocul
recombin
vsv
viru
express
ovalbumin
rna
persist
lung
spleen
lymph
node
week
publish
studi
pig
experiment
infect
rvsvdgzebovgp
viru
present
site
intraderm
inocul
snout
drain
lymph
node
tissu
day
clear
day
anoth
unpublish
studi
young
pig
inocul
high
dose
wtvsv
vaccin
viru
intraderm
inject
snout
oronas
instil
result
vsvlike
ill
group
howev
vaccin
viru
infect
character
delay
onset
lesion
lower
antibodi
respons
pig
transmit
vaccin
viru
contact
wherea
wtvsv
caus
higher
fever
earli
diseas
express
high
level
antibodi
transmiss
contact
studi
suscept
livestock
vaccin
viru
plan
viru
inocula
repres
potenti
exposur
match
level
viremia
shed
human
vaccine
wtvsv
reservoir
insect
transmiss
rvsvdgzebovgp
bloodfeed
arthropod
consid
highli
unlik
rvsvdgzebovgp
viremia
human
gener
threshold
infect
bloodfeed
arthropod
ie
plaqueform
unitsml
moreov
rvsvdgzebovgp
vaccin
viru
replic
mosquito
sandfli
culicoid
cell
cultur
vitro
culex
aed
anophel
mosquito
inocul
intrathorac
rout
culex
aed
mosquito
fed
blood
contain
vaccin
viru
titer
sever
plaqu
form
unit
pfu
concentr
would
observ
vaccin
individu
fail
becom
infect
contrast
wtvsv
replic
intrathorac
inocul
oral
ingest
viru
evid
safeti
pregnanc
current
limit
evid
relat
safeti
rvsvdgzebovgp
vaccin
pregnanc
human
pregnant
women
exclud
clinic
trial
avail
data
women
becam
pregnant
trial
review
world
health
organ
strateg
advisori
group
expert
meet
octob
see
report
cite
preliminari
recommend
development
reproduct
toxicolog
studi
rvsvdgzebovgp
vaccin
perform
rat
model
virem
infect
induc
gestat
administr
pfuanim
show
effect
mate
fertil
fetal
develop
follow
either
singl
multipl
dose
vector
accommod
multigen
insert
sever
vector
requir
multigen
vaccin
rvsvdgzebovgp
multigen
howev
rvsv
known
effici
express
multipl
differ
protein
incorpor
effici
membran
protein
vsv
without
coincorpor
vsv
g
protein
known
effect
preexist
immun
take
safeti
efficaci
anim
model
rvsvdgzebovgp
vaccin
intend
singledos
primari
immun
sinc
vsv
g
protein
delet
vaccin
viru
restrict
preexist
antibodi
vsv
antivector
immun
base
antibodi
cell
backbon
vsv
protein
n
ns
l
could
theoret
restrict
replic
reduc
immun
respons
howev
avail
experiment
data
indic
like
problem
reus
vector
immun
differ
foreign
transmembran
protein
therefor
like
possibl
empir
demonstr
nonhuman
primat
boost
vector
may
blunt
immun
incorpor
foreign
protein
ie
zebov
gp
given
face
high
level
antibodi
observ
live
attenu
vaccin
interv
boost
requir
establish
vsv
present
continent
africa
europ
known
antigenicallyrel
vesiculovirus
present
region
would
provid
antivector
immun
us
latin
america
antibodi
vsv
present
studi
rvsvdgzebovgp
vaccin
immun
respons
vsv
seroposit
versu
seroneg
human
show
impact
preexist
vsv
antibodi
antizebovgp
igg
antibodi
respons
phase
trial
second
inject
rvsvdgzebovgp
given
month
first
dose
time
peak
antibodi
develop
boost
igg
neutral
antibodi
level
observ
although
would
expect
foldincreas
less
observ
initi
inocul
rvsvdgzebovgp
viru
rescu
transfect
step
plaquepurifi
cgmp
condit
vero
cell
cgmp
master
cell
bank
plaquepurifi
clone
gp
sequenc
ident
start
plasmid
amplifi
vero
cell
make
premast
seed
viru
pmsv
pmsv
use
infect
vero
cell
product
master
viru
seed
vaccin
product
mv
use
infect
vero
cell
grown
roller
bottl
mv
passag
count
transfect
step
vector
produc
accept
cell
substrat
vector
grow
high
titer
pfuml
vero
cell
latter
tsefre
stock
use
product
multipl
licens
vaccin
includ
live
attenu
vaccin
eg
oral
polio
smallpox
dengu
japanes
enceph
rotaviru
describ
product
process
mv
use
infect
vero
cell
grown
roller
bottl
cell
cultur
medium
harvest
h
infect
viru
harvest
purifi
depth
filtrat
benzonas
recombin
trypsin
digest
follow
addit
trypsin
inhibitor
ultrafiltr
purifi
drug
substanc
dilut
desir
potenc
mm
tri
mgml
recombin
human
serum
albumin
ph
constitut
drug
product
latter
fill
ml
glass
vial
extract
volum
ml
frozen
puritypotenti
contamin
purif
process
well
defin
document
level
host
cell
dna
low
ngvaccin
dose
level
residu
host
cell
protein
benzonas
trypsin
low
next
gener
sequenc
perform
show
sequenc
ebola
gp
ident
origin
plasmid
use
construct
viru
wtvsv
genom
detect
largescal
manufactur
feasibl
current
manufactur
scale
roller
bottl
scale
drug
substanc
batch
size
approxim
dose
ip
ye
multipl
publish
unpublish
studi
mous
guinea
pig
nhp
model
demonstr
immunogen
rvsvdgzebovgp
gp
rvsv
vector
express
foreign
gene
protect
lethal
challeng
zebov
virus
correspond
respect
transgen
rvsvdgzebovgp
vaccin
highli
immunogen
across
wide
dose
rang
pfu
protect
virtual
nhp
im
challeng
ld
virul
challeng
strain
zebov
rvsvdgzebovgp
gp
vaccin
nhp
surviv
challeng
anim
viremia
show
mild
clinic
sign
surviv
sinc
surviv
frequent
outcom
challeng
difficult
determin
immun
correl
protect
immun
area
activ
studi
one
publish
report
surviv
mice
guinea
pig
nhp
significantli
higher
antibodi
level
prechalleng
day
challeng
nonsurvivor
complet
partial
protect
achiev
singl
dose
rvsvdgzebovgp
given
earli
three
day
prior
challeng
nhp
igg
antibodi
observ
innat
adapt
mechan
respons
earli
protect
model
fulli
defin
earli
protect
may
due
innat
immun
respons
sinc
protect
heterolog
filoviru
marburg
document
adapt
respons
igg
neutral
antibodi
appear
day
im
vaccin
human
anim
experiment
studi
shown
antibodi
oppos
cell
critic
protect
futur
infect
neutral
igm
antibodi
also
suggest
play
import
role
protect
known
biodistribut
cglp
biodistribut
studi
cynomolgu
macaqu
perform
use
rvsvdgzebovgp
inocul
im
pfu
anim
perfus
remov
blood
tissu
test
rna
qrtpcr
vsv
np
gene
amplicon
infecti
viru
plaqu
assay
h
inocul
vector
rna
detect
varieti
tissu
indic
pantrop
natur
infect
adren
gland
aorta
bone
marrow
lung
inject
site
muscl
liver
lymph
node
spleen
pancrea
ovari
testicl
metacarpophalang
joint
skin
inject
site
blood
rvsvdgzebovgpvaccin
anim
highest
level
blood
lymphoid
tissu
copiesml
day
tissu
spleen
lymph
node
ileum
posit
rna
lower
level
copiesml
persist
end
studi
day
infecti
viru
detect
plaqu
assay
bone
marrow
inject
site
muscl
femor
lymph
node
spleen
skin
inject
site
pfug
evid
viral
replic
later
time
point
measur
day
viral
rna
day
gener
confin
tissu
lack
potenti
shed
excret
secret
show
evid
distribut
brain
spinal
cord
time
point
vaccin
viru
present
blood
nhp
human
given
nomin
clinic
dose
vaccin
pfu
im
first
day
vaccin
occasion
day
rare
day
time
subject
igg
antibodi
virusinduc
arthriti
andor
skin
mucos
lesion
includ
vesicular
lesion
petechi
purpura
note
small
proport
vaccine
onset
gener
week
inocul
see
detail
section
vaccin
viru
identifi
vesicl
fluid
well
keratinocyt
site
dermal
lesion
neurovirul
studi
conduct
ye
neurovirul
test
perform
nhp
intrathalam
inject
although
perform
accord
glp
studi
design
similar
use
assess
live
attenu
vaccin
includ
polio
yellow
fever
rvsvdgzebovgp
highli
attenu
compar
wtvsv
test
neonat
miinocul
ic
ip
rout
sure
vivo
test
adventiti
agent
develop
fatal
ill
wean
anim
resist
reason
vivo
test
adventiti
agent
infant
mice
perform
biodistribut
studi
nhp
section
neuroinvas
despit
high
level
viru
bloodstream
copiesml
evid
vector
gener
benefici
immun
respons
ebolaviru
anoth
diseas
speci
includ
rodent
nhp
human
develop
robust
zebovgpspecif
antibodi
respons
inocul
rvsvdgzebovgp
vaccin
across
wide
rang
dose
immun
respons
associ
nearli
protect
challeng
experiment
model
protect
ebolaviru
diseas
human
doserang
studi
nhp
shown
seroconvers
high
antibodi
titer
across
wide
dose
rang
pfu
given
singl
im
inocul
macaqu
also
develop
cell
respons
protect
antibodydepend
shown
studi
vaccin
macaqu
deplet
cell
immun
abrog
protect
wherea
deplet
cell
see
also
section
human
human
develop
igg
viru
neutral
antibodi
singl
dose
doserang
studi
shown
high
gp
elisa
antibodi
titer
across
wide
dose
rang
pfu
given
singl
im
inocul
igg
antibodi
titer
statist
higher
dose
pfu
compar
lower
dose
igg
antibodi
nomin
clinic
dose
pfu
appear
day
peak
day
remain
stabl
declin
slightli
year
seroconvers
defin
fold
increas
baselin
minimum
valu
euml
occur
subject
geometr
mean
endpoint
igg
titer
day
fold
higher
neg
nonirradi
baselin
approxim
euml
valid
assay
neutral
antibodi
measur
pseudovirion
neutral
assay
psvna
increas
day
decreas
subsequ
neutral
antibodi
plaqu
reduct
neutral
prnt
remain
elev
due
varianc
inher
assay
prnt
assay
valid
correl
gpelisa
doserang
studi
human
shown
high
prnt
antibodi
titer
across
wide
dose
rang
pfu
given
singl
im
inocul
prnt
antibodi
nomin
clinic
dose
pfu
appear
day
peak
day
remain
stabl
declin
slightli
year
seroconvers
defin
fold
increas
baselin
occur
subject
geometr
mean
titer
day
fold
higher
baselin
approxim
continu
next
page
known
replic
transmiss
pathogen
vector
healthi
peopl
ye
rvsvdgzebovgp
administ
healthi
particip
includ
approxim
children
year
thirteen
phase
clinic
trial
rvsvdgzebovgp
gener
well
toler
inject
site
reaction
follow
vaccin
common
gener
mild
common
system
advers
event
ae
includ
fever
headach
myalgia
arthralgia
fatigu
joint
skin
advers
event
describ
subject
clinic
trial
ae
mostli
mild
moder
sever
short
durat
except
joint
event
may
last
week
month
rare
case
report
persist
year
preliminari
analys
suggest
slightli
increas
risk
develop
joint
event
women
subject
medic
histori
joint
issu
transient
decreas
white
blood
cell
also
observ
increas
risk
infect
report
rvsvdgzebovgp
viremia
base
upon
rna
detect
detect
almost
subject
first
day
follow
vaccin
studi
assess
appear
less
common
day
postvaccin
shed
rvsvdgzebovgp
base
upon
rna
detect
rare
observ
saliva
urin
skin
vesicl
adult
vaccine
observ
frequent
among
adolesc
children
immunocompromis
unknown
rvsvdgzebovgp
test
small
number
hiv
individu
phase
program
test
addit
hiv
subject
ongo
neonat
infant
children
unknown
preliminari
data
approxim
children
year
age
receiv
nomin
dose
pfu
rvsvdgzebovgp
vaccin
suggest
similar
safeti
profil
seen
adult
subject
trial
rvsvdgzebovgp
larger
number
adolesc
children
year
age
progress
elderli
unknown
age
cutoff
inclus
phase
iiii
trial
vari
major
trial
limit
maximum
age
year
age
less
total
number
elderli
subject
therefor
limit
ring
vaccin
trial
guinea
includ
elderli
subject
year
age
safeti
profil
gener
consist
across
age
group
studi
immunogen
evalu
immun
respons
consist
across
age
group
data
subject
year
age
pregnanc
known
effect
preexist
immun
take
safeti
efficaci
human
studi
differ
insert
ye
see
section
delet
vsv
g
protein
elimin
antivector
immun
mediat
neutral
antibodi
vsv
see
section
phase
data
demonstr
immun
respons
zebovgp
boost
second
dose
rvsvdgzebovgp
name
nonhiv
vaccin
use
vector
describ
public
health
consider
rvsv
vector
yet
test
human
clinic
trial
diseas
hiv
zebov
direct
public
health
consider
remain
rvsv
ebola
vaccin
unlik
use
one
rvsv
vaccin
compromis
futur
use
similar
rvsv
vaccin
express
differ
transmembran
protein
particularli
vector
contain
residu
vsv
g
protein
shown
studi
sequenti
immun
nhp
rvsvlassa
rvsvzebov
two
seriou
advers
event
report
anaphylaxi
across
program
subject
vaccin
phase
trial
trial
plu
expand
access
protocol
one
appear
associ
administr
amoxicillin
differ
indic
second
case
subject
develop
gener
pruritu
urticaria
oedema
face
lip
h
vaccin
subject
present
follow
day
treat
steroid
improv
without
hospit
immunocompromis
unknown
unknown
preliminari
data
well
control
hiv
individu
vaccin
liberia
context
outbreak
suggest
safeti
profil
similar
hivsubject
addit
trial
larger
number
hiv
individu
ongo
toxic
seen
immunocompromis
shiv
infect
macaqu
neonat
infant
children
unknown
unknown
preliminari
data
demonstr
similar
safeti
children
older
year
age
compar
adult
howev
date
far
fewer
children
vaccin
multicent
studi
larg
number
children
infant
progress
elderli
unknown
unknown
age
cutoff
inclus
phase
iiii
trial
vari
major
trial
limit
maximum
age
year
age
less
total
number
elderli
subject
therefor
limit
ring
vaccin
trial
guinea
includ
elderli
subject
year
age
safeti
profil
gener
consist
across
age
group
studi
immunogen
evalu
immun
respons
consist
across
age
group
data
subject
year
age
pregnanc
unborn
unknown
unknown
pregnant
women
exclud
clinic
trial
avail
data
women
becam
pregnant
trial
review
world
health
organ
strateg
advisori
group
expert
meet
octob
strive
studi
sierra
leon
total
pregnanc
within
month
enrol
women
whose
birth
outcom
known
signal
untoward
effect
vaccin
abnorm
observ
glp
development
reproduct
toxic
studi
rat
suscept
popul
unknown
limit
number
person
year
age
enrol
guinea
ring
vaccin
trial
safeti
profil
popul
appear
similar
seen
subject
year
age
preliminari
analys
suggest
slightli
increas
risk
develop
joint
event
women
subject
medic
histori
joint
issu
risk
neurotoxicityneuroinvas
cardiac
effect
minim
delet
vsv
g
protein
markedli
reduc
neurotrop
neurovirul
recombin
vector
anim
model
toxic
intrathalam
inocul
nhp
neuroinvas
biodistribut
studi
nhp
inocul
im
pfu
see
section
minim
transient
viremia
level
human
inocul
pfu
minim
potenti
neuroinvas
across
blood
brain
barrier
potenti
shed
transmiss
risk
group
shed
saliva
urin
low
shed
saliva
urin
appear
dose
relat
even
highest
dose
test
shed
infrequ
present
low
level
copiesml
equat
pfuml
adult
may
higher
children
adolesc
transmiss
risk
appear
low
inject
site
reaction
high
subject
report
pain
major
mild
moder
selflimit
approxim
subject
report
inject
site
swell
erythema
also
mild
moder
selflimit
system
reaction
mild
moder
intens
transient
fever
chill
fatigu
headach
myalgia
arthralgia
lymphopenia
myalgia
fatigu
headach
fever
chill
lymphopenia
larg
minor
subject
within
first
sever
day
vaccin
resolv
within
one
week
major
mild
moder
intens
syndrom
associ
viremia
signatur
monocyteactiv
cytokineschemokin
tnfa
effect
dosedepend
one
two
week
follow
vaccin
trial
includ
pivot
phase
safeti
studi
specif
surveil
joint
skin
advers
event
subject
also
experi
arthriti
andor
rash
case
may
vesicular
purpur
case
viral
rna
identifi
immunohistochemistri
andor
detect
vaccin
viru
rna
rtpcr
joint
skinvesicl
one
phase
studi
incid
oligoarthr
high
reason
differ
well
understood
open
label
safeti
studi
sierra
leon
strive
complain
joint
pain
interv
day
vaccin
oligoarthr
typic
onset
day
distinguish
arthralgia
occur
earlier
vaccin
higher
frequenc
without
object
physic
sign
tender
swell
target
dose
associ
releas
specif
base
minim
dose
demonstr
efficaci
maximum
dose
demonstr
safe
clinic
trial
final
target
potenc
valu
associ
specif
deriv
test
valid
potenc
assay
differ
nomin
dose
report
literatur
clinic
trial
eg
nomin
dose
pfu
deriv
nonvalid
assay
highest
tcidml
use
cell
toxic
maximum
vivo
toxic
unknown
human
receiv
nomin
dose
pfu
measur
nonvalid
assay
vaccin
gener
well
toler
local
system
advers
event
dose
depend
vaccin
associ
arthriti
appear
doseindepend
toxic
observ
macaqu
dose
pfu
measur
nonvalid
assay
differ
demograph
affect
differ
preliminari
analys
suggest
incid
arthriti
may
fold
higher
femal
subject
subject
medic
histori
joint
problem
x
key
aspect
phase
clinic
trial
engag
particip
detail
templat
overal
administ
select
nomin
dose
pfu
rvsvdgzebovgp
vaccin
proven
safe
well
toler
first
day
vaccin
mani
vaccine
experi
acutephas
reaction
fever
headach
myalgia
arthralgia
short
durat
period
associ
lowlevel
viremia
activ
antivir
gene
increas
level
chemokin
cytokin
oligoarthr
rash
appear
second
week
occur
minor
subject
typic
mildmoder
sever
selflimit
vesicular
mucos
lesion
infrequ
arthriti
skin
event
appear
reflect
direct
viral
injuri
inflamm
immunopatholog
basi
new
vaccin
rare
advers
event
may
detect
accumul
larg
safeti
data
base
million
person
immun
clinic
trial
shown
vaccin
highli
immunogen
across
broad
dose
rang
pfu
subject
develop
igg
bind
antibodi
elisa
use
recombin
gp
antigen
neutral
antibodi
use
sever
differ
method
predominantli
plaqu
reduct
method
pseudotyp
viru
eg
rvsvdgzebovgp
tabl
lower
level
neutral
antibodi
wildtyp
ebola
observ
possibl
due
competit
sgp
igg
neutral
antibodi
appear
day
peak
day
plateau
thereaft
least
month
z
studi
human
nhp
use
im
rout
administr
comparison
subcutan
sc
deliveri
simpli
reflect
rapid
pace
develop
vaccin
aa
efficaci
rvsvdgzebovgp
vaccin
demonstr
larg
ring
vaccin
trial
guinea
contact
ebola
case
contact
contact
random
receiv
singl
inject
pfu
rvsvdgzebovgp
vaccin
immedi
delay
analysi
efficaci
random
ring
compar
vaccin
subject
immedi
arm
subject
ring
elig
subject
consent
day
delay
arm
subject
ring
ten
case
confirm
evd
ring
observ
elig
subject
delay
vaccin
arm
consent
day
case
evd
occur
vaccin
subject
immedi
arm
day
vaccin
calcul
vaccin
efficaci
analysi
ci
p
remark
trial
conduct
tail
end
west
african
epidem
underpin
regulatori
review
toward
licensur
vaccin
well
preapprov
use
control
outbreak
ebola
viru
diseas
ab
summari
clinic
trial
employ
rvsvdgzebovgp
provid
tabl
find
opinion
conclus
assert
contain
consensu
document
individu
member
work
group
necessarili
repres
offici
posit
particip
organ
eg
govern
univers
corpor
constru
repres
agenc
determin
polici
